Bioxcel Therapeutics Inc (BTAI)

Dec 17, 2024

Bioxcel therapeutics CEO sells shares worth $1,131 By Investing.com - Investing.com Australia

Dec 17, 2024

Dec 17, 2024

Bioxcel therapeutics' chief scientific officer sells $151 worth of stock By Investing.com - Investing.com Canada

Dec 17, 2024

Dec 17, 2024

Bioxcel therapeutics CFO Richard Steinhart sells $206 in stock - Investing.com India

Dec 17, 2024

Dec 17, 2024

Bioxcel therapeutics executive sells $153 in stock - Investing.com

Dec 17, 2024

Dec 17, 2024

Bioxcel therapeutics CEO sells shares worth $1,131 - Investing.com

Dec 17, 2024

Dec 17, 2024

Bioxcel therapeutics exec sells $58 in stock By Investing.com - Investing.com UK

Dec 17, 2024

Dec 16, 2024

BioXcel Therapeutics stock hits 52-week low at $0.35 - Investing.com India

Dec 16, 2024

Dec 05, 2024

BioXcel Therapeutics (STU:BX2) 5-Day RSI : 7.74 (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024

Dec 05, 2024

BioXcel Therapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada

Dec 05, 2024

Dec 04, 2024

BioXcel Therapeutics stock hits 52-week low at $0.4 - Investing.com India

Dec 04, 2024

Nov 25, 2024

BioXcel Therapeutics announces pricing of $7M public offering - MSN

Nov 25, 2024

Nov 23, 2024

BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia

Nov 23, 2024

Nov 22, 2024

BioXcel Therapeutics Prices of $7 Million Public Offering - citybiz

Nov 22, 2024

Nov 22, 2024

BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India

Nov 22, 2024

Nov 22, 2024

BioXcel Therapeutics announces $7M public offering - Hartford Business Journal

Nov 22, 2024

Nov 22, 2024

BioXcel Prices New Offering - Baystreet.ca

Nov 22, 2024

Nov 22, 2024

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewswire

Nov 22, 2024

Nov 22, 2024

BioXcel Therapeutics Announces $7M Public Offering at $0.48 Per Share with Warrants | BTAI Stock News - StockTitan

Nov 22, 2024

Nov 21, 2024

BioXcel Therapeutics amends credit agreement, issues new warrants - Investing.com

Nov 21, 2024

Nov 21, 2024

BioXcel Therapeutics amends credit agreement, issues new warrants By Investing.com - Investing.com Canada

Nov 21, 2024

Nov 21, 2024

BioXcel Therapeutics Announces Proposed Public Offering - GlobeNewswire

Nov 21, 2024

Nov 21, 2024

BioXcel Therapeutics Announces Proposed Public Offering - Benzinga

Nov 21, 2024

Nov 21, 2024

BioXcel Therapeutics Launches Public Offering to Fund Critical Clinical Trials | BTAI Stock News - StockTitan

Nov 21, 2024

Nov 20, 2024

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024

Nov 18, 2024

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 18, 2024

Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada

Nov 15, 2024

Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance

Nov 15, 2024

Nov 15, 2024

BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 14, 2024

BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 14, 2024

Nov 14, 2024

500: Something went wrong - Investing.com India

Nov 14, 2024

Nov 14, 2024

Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com

Nov 14, 2024

Nov 14, 2024

Earnings call: BioXcel Therapeutics reports Q3 2024 financials By Investing.com - Investing.com UK

Nov 14, 2024

Nov 14, 2024

BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada

Nov 14, 2024

Nov 14, 2024

BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 14, 2024

Nov 14, 2024

BioXcel Q3 Revenue Drops 37%, but Net Loss Narrows Significantly to $13.7M | BTAI Stock News - StockTitan

Nov 14, 2024

Nov 14, 2024

Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World

Nov 14, 2024

Nov 13, 2024

What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World

Nov 13, 2024

Nov 12, 2024

BioXcel advances trials for acute agitation treatments - Investing.com India

Nov 12, 2024

Nov 12, 2024

BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK

Nov 12, 2024

Nov 12, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times

Nov 12, 2024

Nov 12, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire

Nov 12, 2024

Nov 12, 2024

BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan

Nov 12, 2024